280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial Meeting Abstract
| Authors: | Eto, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Oya, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; Schmidinger, M.; Tomita, Y.; Umeyama, Y.; Ellers-Lenz, B.; Hoffman, J.; Larkin, J. |
| Abstract Title: | 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial |
| Meeting Title: | ESMO Asia Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2024 Dec 6-8 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-12-01 |
| Start Page: | S1512 |
| End Page: | S1513 |
| Language: | English |
| ACCESSION: | WOS:001401985200270 |
| DOI: | 10.1016/j.annonc.2024.10.300 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 280P -- Source: Wos |
